Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 4

Research Article

Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 4

Multivariate analysis of clinicopathological variables of neutropenia.

Variables Before propensity matching After propensity matching
OR 95% CI OR 95% CI

Age1.0060.987–1.0260.5160.998 0.982–1.0140.777
Chemotherapy regimens
 11 1
 20.5920.336–1.0450.0710.580 0.361–0.9310.024
 33.8532.245–6.6140.0000014.184 2.725–6.424<0.0001
 42.1241.252–3.6060.0051.984 1.282–3.0720.002
TNM stage
 II1.1570.797–1.6780.4431.554 1.139–2.1200.005
 III and IV2.0290.989–4.1640.0541.683 0.952–2.9670.073
Neoadjuvant chemotherapy0.9620.523–1.7680.9010.896 0.521–1.5410.691
ER1.1340.600–2.1440.6980.932 0.556–1.5610.789
PR0.9570.533–1.7180.8830.969 0.602–1.5600.898
HER-20.9620.599–1.5460.8731.090 0.722–1.6450.682
Ki670.8590.582–1.2660.4421.022 0.745–1.4020.893
TCM treatment0.6070.400–0.9230.0190.741 0.554–0.9920.044

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.